

## Exploring the Current and Changing Paradigm for the Management of Newly Diagnosed Diffuse Large B-Cell Lymphoma (Faculty Presentations)

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- Which of the following is targeted by the antibody-drug conjugate polatuzumab vedotin?
  - CD19
  - CD47
  - CD79b
  - Exportin 1 (XPO1)
- In the Phase III POLARIX study comparing polatuzumab vedotin combined with rituximab, cyclophosphamide, doxorubicin and prednisone (Pola-R-CHP) versus standard R-CHOP in patients with previously untreated intermediate- or high-risk diffuse large B-cell lymphoma, what were the primary observations in terms of safety?
  - Pola-R-CHP was associated with significantly more peripheral neuropathy
  - Pola-R-CHP was associated with significantly more anemia
  - Significantly more patients discontinued Pola-R-CHP due to treatment-related adverse events
  - All of the above
  - The safety profile of Pola-R-CHP and R-CHOP were essentially similar
- The Phase III POLARIX study demonstrated a significant 27% improvement in the primary endpoint of progression-free survival (PFS) with Pola-R-CHP compared to standard R-CHOP. What was observed in subgroup analysis of PFS?
  - Greater benefits of Pola-R-CHP in patients with higher IPI scores (IPI 3-5) than lower IPI scores (IPI 2)
  - Greater benefits of Pola-R-CHP in patients with activated B-cell cell-of-origin
  - Greater benefits of Pola-R-CHP in patients with germinal center B-cell cell-of-origin
  - A and B
  - A and C
  - No difference in the benefits of Pola-R-CHP based on IPI or cell-of-origin
- In which of the following settings was the Phase II ZUMA-12 trial evaluating axicabtagene ciloleucel in patients with large B-cell lymphoma (LBCL) conducted?
  - As a component of a third-line treatment regimen for patients with high-risk LBCL
  - As a component of a second-line treatment regimen for patients with high-risk LBCL
  - As a component of a first-line treatment regimen for patients with high-risk LBCL
- In which of the following settings is the ongoing Phase III POLAR BEAR trial evaluating mini-R-CHOP versus mini-R-CHP with polatuzumab vedotin for patients with DLBCL being conducted?
  - Third-line therapy
  - Third-line therapy in elderly or frail patients
  - Second-line therapy in elderly or frail patients
  - First-line therapy
  - First-line therapy in elderly or frail patients